Supporting Information

Palladium-Catalyzed C8-H Alkoxycarbonylation of 1-

Naphthylamines with Alkyl chloroformates

Yaqi Shi,[†] Fan Yang,^{*,†} and Yangjie Wu^{*,†}

[†]College of Chemistry, Green Catalysis Center, Henan Key Laboratory of Chemical Biology and Organic Chemistry, Key Laboratory of Applied Chemistry of Henan Universities, Zhengzhou University, Zhengzhou 450052, PR China

E-mail: yangf@zzu.edu.cn; wyj@zzu.edu.cn

Table of Contents

1. General Information	S2
2. Optimization of Reaction Conditions	S2
3. Experimental Section	S 3
3.1. Typical procedure for the synthesis of substrate 1a	
3.2. Typical procedure for the product 3aa	
3.3. Typical procedure for the product 4a	
3.4. Typical procedure for the product 8a	
3.5. The experiment of trapping the radicals	
3.6. Kinetic isotope effect measurements	
4. Characterization Data of the Products	S8
5. References	S18
6. The Single Crystal X-ray Diffraction Study of 3na	S18
7. Copies of ¹ H and ¹³ C NMR Spectra for the Products	S20

1. General Information

¹H NMR and ¹³C NMR spectra were recorded on a Bruker DPX-400 spectrometer with CDCl₃ as the solvent and TMS as an internal standard. Melting points were measured using a WC-1 microscopic apparatus and are uncorrected. High resolution mass spectra were ensured on an Agilent Technologies 1290-6540 UHPLC/Accurate-Mass Quadrupole Time-of-Flight LC/MS. All solvents were used directly without further purification. Dichloromethane, ethyl acetate, and hexane were used for column chromatography. The commercials were obtained from commercial sources and used as-received without further purification unless otherwise noted.

2. Optimization of Reaction Conditions

HN HN		Pd catalyst (10 mol %) base (2.0 equiv) additive (1.0 equiv) toluene, 120 °C, Ar, 12 h	
1a	2a		3aa
Entry	catalyst	solvent	yield ^b
1	$Pd(OAc)_2$	DCE	0%
2	$Pd(OAc)_2$	CH ₃ CN	0%
3	$Pd(OAc)_2$	toluene	57%
4	$Pd(OAc)_2$	DMSO	0%
5	$Pd(OAc)_2$	1,4-dioxane	0%
6	$Pd(OAc)_2$	CH ₃ OH	0%
7	$Pd(OAc)_2$	DMF	0%
8	$Pd(OAc)_2$	actone	0%
9	Cu(OAc) ₂	toluene	0%
10	Co(OAc) ₂	toluene	0%
11	NiCl ₂	toluene	0%
12	FeCl ₃	toluene	0%
13	$RuCl_2(p-cymene)_2$	toluene	0%
14	PdCl ₂	toluene	43%
15	Pd(TFA) ₂	toluene	45%
16	Pd(CH ₃ CN) ₂ Cl ₂	toluene	32%
17	Pd ₂ dba ₃	toluene	0%
18	PdI ₂	toluene	26%

Table S1. Optimization of Solvent and Catalyst^a

^a Reaction conditions: **1a** (0.1 mmol), **2a** (3.0 equiv), catalysts (10 mol %), NaOAc (2.0 equiv) in solvent (1.0 mL) at 120 °C under argon for 12 h. ^b Isolated yield.

Table S2. Optimization of Base and Additive^a

Entry	base	additive	yield ^b
1	NaHCO ₃	-	18%
2	Na ₂ CO ₃	-	40%
3	KOAc	-	75%
4	K ₂ CO ₃	-	43%
5	Na ₃ PO ₄	-	41%
6	Na ₂ HPO ₄	-	35%
7	NaH ₂ PO ₄	-	22%
8	PivONa	-	0%
9	Cs ₂ CO ₃	-	0%
10	pyridine	-	0%
11	DBU	-	0%
12	NEt ₃	-	0%
13	'BuONa	-	47%
14	EtONa	-	44%
15	NaOAc	I_2	0%
16	NaOAc	NaI	81%
17	NaOAc	KI	73%
18	NaOAc	AgSbF ₆	16%
19°	NaOAc	NaI	68%
20 ^d	NaOAc	NaI	72%
21 ^e	NaOAc	NaI	88%
19 ^{e,f}	NaOAc	NaI	48%
20 ^{e,g}	NaOAc	NaI	77%

^a Reaction conditions: **1a** (0.1 mmol), **2a** (3.0 equiv), Pd(OAc)₂ (10 mol %), base (2.0 equiv) and additive (1.0 equiv) in toluene (1.0 mL) at 120 °C under argon for 12 h. ^b Isolated yield. ^cAt a additive loading of 30 mol %. ^dAt a additive loading of 50 mol %. ^e Pd(OAc)₂ (15 mol %). ^fAt 100 °C. ^gUnder air.

3. Experimental Section

3.1. Typical procedure for the synthesis of substrate 1a

A 100 mL two-necked round-bottom flask was equipped with a magnetic stir bar and charged with 1-naphthylamine (20 mmol, 2.86 g), picolinic acid (1.1 equiv, 2.70 g), N,N-dimethyl-4-aminopyridine (DMAP, 0.1 equiv, 0.244 g) in 30 mL anhydrous CH_2Cl_2 at 0 °C. After EDCI (4.20 g, 1.1 equiv) in CH_2Cl_2 (20 mL) was added dropwise to the solution under a nitrogen atmosphere, the reaction was then warmed to room temperature, stirred for 12 h and quenched with water (30 mL). The reaction mixture was extracted with CH_2Cl_2 (3 × 20 mL), and the combined organic

solvent was dried over Na_2SO_4 , filtered and concentrated under reduced pressure. The resulting residue was purified by column chromatography (hexane/ethyl acetate = 3:1) (V/V) to afford the pure product **1a** as a white solid (4.42 g, 89%).

All amides were prepared from the corresponding 1-naphthylamine derivatives and 2-picolinic acid according to the reported procedure.¹

3.2. Typical procedure for the product 3aa

A Schlenk tube was equipped with a magnetic stir bar and charged with N-(naphthalen-1yl)picolinamide **1a** (0.1 mmol, 24.8 mg), **2a** (0.3 mmol, 41 μ L), NaOAc (0.2 mmol, 16 mg), Pd(OAc)₂ (0.015 mmol, 3.3 mg), NaI (0.1 mmol, 15 mg) in toluene (1.0 mL). The resulting mixture was sealed under argon, heated at 120 °C for 12 h, and cooled to room temperature. Upon completion, CH₂Cl₂ (20 mL) was added to the reaction system, and the resulting mixture was filtered through a pad of Celite. After the organic material was concentrated in vacuum, the product was purified by column chromatography on silica gel (100–200 mesh) using hexane/EtOAc as an eluent (5:1, V/V) to afford the pure product **3aa**.

3.3. Typical procedure for the product 4a



A mixture of **3aa** (66.8 mg, 0.2 mmol, 1.0 equiv) and NaOH (240 mg, 6 mmol, 30 equiv) was heated in ethanol (3.0 mL) for 12 h at 80 °C. After the mixture was cooled to room temperature and diluted with water (3.0 mL), the solution of diluted hydrochloric acid was added until it was acidic. The saturated NaHCO₃ solution was then added until the pH value was about 7. The mixture was then extracted with CH_2Cl_2 and dried over anhydrous Na_2SO_4 . After the organic material was concentrated in vacuum, the product was purified by column chromatography on silica gel (100–200 mesh) using hexane/EtOAc as an eluent (3:1, V/V) to afford the pure product **4a**.

3.4. Typical procedure for the product 8a



8a (BET bromodomain inhibitor)

To a solution of **4a** (169 mg, 1.0 mmol, 1.0 equiv) in DMF (2.5 mL), NaH (36 mg, 1.5 mmol, 1.5 equiv) was added at 0 °C. After stirred for 10 min at 0 °C, iodoethane (96 μ L, 1.2 mmol, 1.2 equiv) was added dropwise into the solution and the reaction mixture was stirred at room temperature. After the reaction was completed, the resulting mixture was poured into H₂O and extracted with ethyl acetate. The organic material was dried over Na₂SO₄ and concentrated in vacuum, and the product was purified by column chromatography on silica gel (100–200 mesh) using hexane/EtOAc as an eluent (5:1, V/V) to afford the pure product **5a**.

To a solution of **5a** (189 mg, 0.96 mmol, 1.0 equiv) in AcOH (2.5 mL), HNO₃ (61 mg, 0.96 mmol, 1.0 equiv) was added at 0 °C and then the reaction mixture was stirred at 50 °C for 1 h. After the reaction was completed, the reaction mixture was cooled to room temperature. The mixture was extracted with ethyl acetate, dried over anhydrous Na_2SO_4 and concentrated in vacuo, and the product was purified by column chromatography on silica gel (100–200 mesh) using hexane/EtOAc as an eluent (5:1, V/V) to afford the pure product **6a**.

A mixture of iron powder (179 mg, 3.2 mmol, 5.0 equiv) and NH₄Cl (68 mg, 1.28 mmol, 2.0 equiv) in a mixture of AcOH/water (2 mL/8 mL) was heated at 50 °C for 5 min. Subsequently, **6a** (155 mg, 0.64 mmol, 1.0 equiv) was dissolved in DMF (2 mL) and added to the reaction mixture. After completion, the mixture was cooled to room temperature, extracted with ethyl acetate. After the organic layer was washed with brine, dried over Na₂SO₄ and filtered, the filtrate was concentrated in vacuo. The product was purified by column chromatography on silica gel (100–200 mesh) using hexane/EtOAc as an eluent (3:1, V/V) to afford the pure product **7a**.

A mixture of **7a** (105 mg, 0.5 mmol, 1.0 equiv) and 5-bromo-2-methoxybenzenesulfonyl chloride (170 mg, 0.6 mmol, 1.2 equiv) in CH_2Cl_2 (10 mL) was added in pyridine (0.5 mL) and stirred at room temperature for 2 h. The mixture was extracted with CH_2Cl_2 , and the organic layer was washed with brine, dried over anhydrous Na_2SO_4 and filtered. The filtrate was concentrated in vacuo, and the product was purified by column chromatography on silica gel (100–200 mesh) using hexane/EtOAc as an eluent (2:1, V/V) to afford the pure product **8a**.²

3.5. The experiment of trapping the radicals



HRMS (ESI⁺): calcd for $C_{31}H_{35}N_2O_2$ [M+H]⁺: 467.2693, found: 467.2692.



3.6. Kinetic isotope effect measurements

A Schlenk tube was equipped with a magnetic stir bar and charged with N-(naphthalen-1yl)picolinamide **1a** (0.05 mmol, 12.4 mg), **1a**- d_1 (0.05 mmol, 12.4 mg), **2a** (0.3 mmol, 41 µL), NaOAc (0.2 mmol, 16 mg), Pd(OAc)₂ (0.015 mmol, 3.3 mg), NaI (0.1 mmol, 15 mg) in toluene (1.0 mL). The resulting mixture was sealed under Ar, heated at 120 °C for 1 h and cooled to room temperature. Upon completion, CH₂Cl₂ (20 mL) was added to the reaction system, and the resulting mixture was filtered through a pad of Celite. After the organic material was concentrated in vacuum, the product was purified by column chromatography on silica gel (100–200 mesh) using hexane/EtOAc as an eluent (5:1, V/V) to afford the pure product **1a/1a**- d_1 , and then analyzed by ¹H NMR spectrum. The KIE value was calculated as $k_H/k_D = 0.3$.



4. Characterization Data of the Products



Isopropyl 8-(picolinamido)-1-naphthoate, **3aa**: yellow solid (29.4 mg, 88%); mp 110-112 °C; ¹H NMR (400 MHz, CDCl₃) δ 10.37 (s, 1H), 8.72-8.70 (m, 1H), 8.30-8.28 (m, 1H), 7.98 (dd, $J_1 = 8.24$ Hz, $J_2 = 1.12$ Hz, 1H), 7.92-7.88 (m, 2H), 7.84 (d, J = 7.20 Hz, 1H), 7.67-7.62 (m, 2H), 7.49-7.45 (m, 2H), 5.15-5.09 (m, 1H), 1.20 (d, J = 6.28 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 170.8, 163.5, 150.2, 148.1, 137.5, 135.1, 131.9, 131.7, 129.4, 128.3, 127.5, 126.7, 126.5, 126.4, 125.7, 124.6, 122.8, 69.5, 21.6; HRMS (ESI⁺): calcd for C₂₀H₁₉N₂O₃ [M+H]⁺: 335.1390, found: 335.1391.



Isopropyl 8-(3-methylpicolinamido)-1-naphthoate, **3ba**: colorless solid (14.3 mg, 41%); mp 113-115 °C; ¹H NMR (400 MHz, CDCl₃) δ 10.39 (s, 1H), 8.55 (dd, J_I = 4.56 Hz, J_2 = 1.04 Hz, 1H), 7.97 (dd, J_I = 8.24 Hz, J_2 = 1.12 Hz, 1H), 7.88-7.82 (m, 2H), 7.65-7.59 (m, 3H), 7.49-7.45 (m, 1H), 7.40-7.37 (m, 1H), 5.04-4.98 (m, 1H), 2.76 (s, 3H), 1.16 (d, J = 6.28 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 170.8, 165.1, 147.3, 145.5, 141.0, 136.2, 135.1, 132.1, 131.7, 130.0, 128.0, 127.3, 126.8, 126.3, 126.0, 124.5, 69.3, 21.5, 20.7; HRMS (ESI⁺): calcd for C₂₁H₂₁N₂O₃, [M+H]⁺: 349.1547, found: 349.1549.



Isopropyl 8-(6-methylpicolinamido)-1-naphthoate, **3ca**: yellow solid (31.7 mg, 91%); mp 109-110 °C; ¹H NMR (400 MHz, CDCl₃) δ 10.43 (s, 1H), 8.09 (d, *J* = 7.64 Hz, 1H), 7.97 (d, *J* = 8.08 Hz, 1H), 7.90 (d, *J* = 7.40 Hz, 1H), 7.83-7.75 (m, 2H), 7.65-7.58 (m, 2H), 7.46 (t, *J* = 7.62 Hz, 1H), 7.34 (d, *J* = 7.68 Hz, 1H), 5.09-5.02 (m, 1H), 2.70 (s, 3H), 1.13 (d, *J* = 6.28 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 170.7, 163.8, 157.3, 149.4, 137.6, 135.1, 132.0, 129.5, 128.1, 127.4, 126.6, 126.4, 126.2, 125.8, 124.5, 119.8, 69.1, 24.1, 21.6; HRMS (ESI⁺): calcd for C₂₁H₂₁N₂O₃ [M+H]⁺: 349.1547, found: 349.1548.



Isopropyl 8-(5-methoxypicolinamido)-1-naphthoate, **3da**: brown solid (28.8 mg, 79%); mp 76-79 °C; ¹H NMR (400 MHz, CDCl₃) δ 10.18 (s, 1H), 8.36 (d, *J* = 2.80 Hz, 1H), 8.24 (d, *J* = 8.64 Hz, 1H), 7.90 (dd, *J*₁ = 8.24 Hz, *J*₂ = 1.12 Hz, 1H), 7.89 (d, *J* = 7.44, Hz, 1H), 7.83-7.81 (m, 1H), 7.66-7.58 (m, 2H), 7.48-7.45 (m, 1H), 7.33 (dd, *J*₁ = 8.68 Hz, *J*₂ = 2.84 Hz, 1H), 5.15-5.09 (m, 1H), 3.93 (s, 3H), 1.22 (d, *J* = 6.28 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 170.8, 163.4, 158.1, 142.8, 136.4, 135.1, 131.9, 131.8, 129.5, 128.1, 127.3, 126.7, 126.4, 125.8, 124.5, 124.1, 120.3, 69.5, 55.8, 21.6; HRMS (ESI⁺): calcd for C₂₁H₂₁N₂O₄ [M+H]⁺: 365.1496, found: 365.1498.



Isopropyl 8-(5-bromopicolinamido)-1-naphthoate, **3ea**: yellow solid (21.4 mg, 52%); mp 85-87 °C; ¹H NMR (400 MHz, CDCl₃) δ 10.28 (s, 1H), 8.77 (dd, $J_1 = 2.22$ Hz, $J_2 = 0.58$ Hz, 1H), 8.18 (dd, $J_1 = 8.32$ Hz, $J_2 = 0.56$ Hz, 1H), 8.04 (dd, $J_1 = 8.32$ Hz, $J_2 = 2.28$ Hz, 1H), 7.99 (dd, $J_1 = 8.24$ Hz, $J_2 = 1.12$ Hz, 1H), 7.90 (d, J = 7.48 Hz, 1H), 7.84 (d, J = 8.16 Hz, 1H), 7.69 (dd, $J_1 = 7.10$ Hz, J_2 = 1.26 Hz, 1H), 7.61 (t, J = 7.84 Hz, 1H), 7.50-7.46 (m, 1H), 5.18-5.11 (m, 1H), 1.24 (d, J = 6.28Hz, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 170.7, 162.8, 149.2, 148.7, 140.2, 135.1, 132.1, 131.4, 129.2, 128.6, 127.7, 126.7, 126.3, 125.6, 124.6, 124.4, 124.3, 69.5, 21.6; HRMS (ESI⁺): calcd for C₂₀H₁₈BrN₂O₃ [M+H]⁺: 413.0495, found: 413.0497.



Isopropyl 8-(5-chloropicolinamido)-1-naphthoate, **3fa**: yellow solid (18.8 mg, 51%); mp 102-104 °C; ¹H NMR (400 MHz, CDCl₃) δ 10.27 (s, 1H), 8.66 (d, *J* = 2.09 Hz, 1H), 8.25 (d, *J* = 8.27 Hz, 1H), 8.00 (dd, *J*₁ = 8.19 Hz, *J*₂ = 0.88 Hz, 1H), 7.91-7.84 (m, 3H), 7.69 (dd, *J*₁ = 7.11 Hz, *J*₂ = 1.26 Hz, 1H), 7.62 (t, *J* = 7.83 Hz, 1H), 7.50-7.46 (m, 1H), 5.18-5.11 (m, 1H), 1.24 (d, *J* = 6.28 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 170.8, 162.6, 148.4, 147.1, 137.2, 135.4, 135.1, 132.1, 131.5, 129.2, 128.6, 127.7, 126.7, 126.3, 125.6, 124.6, 123.9, 69.5, 21.6; HRMS (ESI⁺): calcd for C₂₀H₁₈ClN₂O₃ [M+H]⁺: 369.1000, found: 369.0998.



Isopropyl 8-(4-chloropicolinamido)-1-naphthoate, **3ga**: white solid (28.3 mg, 77%); mp 146-148 °C; ¹H NMR (400 MHz, CDCl₃) δ 10.35 (s, 1H), 8.61 (d, *J* = 5.24 Hz, 1H), 8.29 (d, *J* = 1.92 Hz, 1H), 8.00-7.98 (m, 1H), 7.91 (d, *J* = 7.44 Hz, 1H), 7.85 (d, *J* = 8.00 Hz, 1H), 7.70-7.68 (m, 1H), 7.62 (t, *J* = 7.82 Hz, 1H), 7.52-7.47 (m, 2H), 5.17-5.11 (m, 1H), 1.23 (d, *J* = 6.28 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 170.7, 162.4, 151.7, 149.0, 146.0, 135.1, 132.2, 131.4, 129.1, 128.7, 127.7, 126.7, 126.4, 125.6, 124.6, 123.5, 69.5, 21.6; HRMS (ESI⁺): calcd for C₂₀H₁₈ClN₂O₃ [M+H]⁺: 369.1000, found: 369.1002.



Isopropyl 8-(quinoline-2-carboxamido)-1-naphthoate, **3ha**: yellow solid (35.3 mg, 92%); mp 93-95 °C; ¹H NMR (400 MHz, CDCl₃) δ 10.67 (s, 1H), 8.40-8.32 (m, 3H), 7.99-7.97 (m, 2H), 7.90 (dd, $J_I = 8.06$ Hz, $J_2 = 1.02$ Hz, 1H), 7.84-7.79 (m, 2H), 7.68-7.60 (m, 3H), 7.49-7.45 (m, 1H), 5.09-5.03 (m, 1H), 1.01 (d, J = 6.28 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 170.9, 163.7, 149.9, 146.5, 137.7, 135.2, 131.9, 130.3, 129.9, 129.5, 129.4, 128.3, 128.2, 127.8, 127.5, 126.6, 126.4, 125.8, 124.6, 119.1, 69.3, 21.5; HRMS (ESI⁺): calcd for C₂₄H₂₁N₂O₃ [M+H]⁺: 385.1547, found: 385.1548.



Isopropyl 8-(isoquinoline-1-carboxamido)-1-naphthoate, **3ia**: colorless solid (16.9 mg, 44%); mp 84-85 °C; ¹H NMR (400 MHz, CDCl₃) δ 10.57 (s, 1H), 9.62-9.59 (m, 1H), 8.63 (d, *J* = 5.52 Hz,

1H), 8.01-7.97 (m, 2H), 7.89-7.84 (m, 3H), 7.75-7.63 (m, 4H), 7.50-7.46 (m, 1H), 5.00-4.94 (m, 1H), 1.08 (d, J = 6.28 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 170.9, 165.1, 148.2, 140.2, 137.5, 135.2, 132.0, 131.9, 130.6, 129.5, 128.9, 128.2, 127.8, 127.5, 127.3, 126.9, 126.8, 126.4, 125.9, 124.8, 124.6, 69.4, 21.5; HRMS (ESI⁺): calcd for C₂₄H₂₁N₂O₃ [M+H]⁺: 385.1547, found: 385.1548.



Isopropyl 8-(pyrimidine-4-carboxamido)-1-naphthoate, **3ja**: yellow oil (7.7 mg, 23%); ¹H NMR (400 MHz, CDCl₃) δ 10.47 (s, 1H), 9.41 (d, J = 1.28 Hz, 1H), 9.04 (d, J = 5.00 Hz, 1H), 8.22 (dd, J_1 = 5.02 Hz, J_2 = 1.34 Hz, 1H), 8.02 (dd, J_1 = 8.22 Hz, J_2 = 1.06 Hz, 1H), 7.93 (d, J = 7.48 Hz, 1H), 7.87 (d, J = 8.08 Hz, 1H), 7.76 (dd, J_1 = 7.12 Hz, J_2 = 1.20 Hz, 1H), 7.63 (t, J = 7.84 Hz, 1H), 7.52-7.48 (m, 1H), 5.24-5.18 (m, 1H), 1.26 (d, J = 6.24 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 170.1, 161.9, 159.4, 157.8, 156.8, 135.2, 132.5, 130.9, 129.2, 128.8, 128.1, 126.8, 126.3, 125.4, 124.7, 119.1, 69.7, 21.6; HRMS (ESI⁺): calcd for C₁₉H₁₈N₃O₃ [M+H]⁺: 336.1343, found: 336.1342.



Isopropyl 5-acetoxy-8-(picolinamido)-1-naphthoate, **3ka**: brown oil (18.4 mg, 47%); ¹H NMR (400 MHz, CDCl₃) δ 10.28 (s, 1H), 8.70 (d, J = 4.52 Hz, 1H), 8.29 (d, J = 7.76 Hz, 1H), 8.06-8.04 (m, 1H), 7.92-7.87 (m, 2H), 7.66 (d, J = 6.28 Hz, 1H), 7.54-7.49 (m, 2H), 7.41 (d, J = 8.20 Hz, 1H), 5.11-5.05 (m, 1H), 2.47 (s, 3H), 1.19 (d, J = 6.28 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 170.4, 169.3, 163.6, 149.9, 148.1, 145.2, 137.5, 129.9, 129.7, 128.5, 128.2, 126.8, 126.6, 126.4, 125.2, 124.6, 122.9, 118.9, 69.7, 21.5, 21.1; HRMS (ESI⁺): calcd for C₂₂H₂₁N₂O₅ [M+H]⁺: 393.1445, found: 393.1444.



Isopropyl 4-methoxy-8-(picolinamido)-1-naphthoate, **3la**: brown solid (25.1 mg, 69%); mp 156-158 °C; ¹H NMR (400 MHz, CDCl₃) δ 10.55 (s, 1H), 8.69 (d, J = 4.56 Hz, 1H), 8.31-8.26 (m, 2H), 7.96 (d, J = 7.32 Hz, 1H), 7.87 (t, = 7.70 Hz, 1H), 7.72 (d, J = 8.08 Hz, 1H), 7.61 (t, = 7.96 Hz,

1H), 7.48-7.45 (m, 1H), 6.76 (d, J = 8.04 Hz, 1H), 5.19-5.12 (m, 1H), 4.00 (s, 3H), 1.21 (d, J = 6.28 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 170.4, 163.5, 158.3, 150.3, 148.1, 137.4, 131.7, 130.4, 127.3, 127.2, 127.0, 126.4, 125.7, 122.8, 121.3, 121.1, 102.3, 69.1, 55.9, 21.6; HRMS (ESI⁺): calcd for C₂₁H₂₁N₂O₄ [M+H]⁺: 365.1496, found: 365.1499.



Isopropyl 4-amino-8-(picolinamido)-1-naphthoate, **3ma**: brown solid (13.3 mg, 38%); mp 130-133 °C; ¹H NMR (400 MHz, CDCl₃) δ 10.78 (s, 1H), 8.72-8.71 (m, 1H), 8.43 (d, *J* = 7.48 Hz, 1H), 8.36 (d, *J* = 7.80 Hz, 1H), 8.00-7.89 (m, 3H), 7.74 (d, *J* = 8.56 Hz, 1H), 7.60-7.52 (m, 3H), 7.01 (s, 1H), 5.12-5.06 (m, 1H), 1.35 (d, *J* = 6.24 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 162.3, 154.0, 149.9, 148.2, 137.8, 133.5, 133.0, 127.0, 126.6, 126.2, 126.1, 122.5, 118.7, 117.3, 116.9, 69.1, 22.2; HRMS (ESI⁺): calcd for C₂₀H₂₀N₃O₃ [M+H]⁺: 350.1499, found: 350.1051.



Isopropyl 5-bromo-8-(picolinamido)-1-naphthoate, **3na**: yellow solid (31.3 mg, 76%); mp 114-116 °C; ¹H NMR (400 MHz, CDCl₃) δ 10.26 (s, 1H), 8.70 (d, *J* = 4.48 Hz, 1H), 8.45 (dd, *J*₁ = 8.52 Hz, *J*₂ = 1.00 Hz, 1H), 8.28 (d, = 7.84 Hz, 1H), 7.93-7.88 (m, 2H), 7.75 (d, *J* = 8.12 Hz, 1H), 7.68 (dd, *J*₁ = 7.04 Hz, *J*₂ = 1.12 Hz, 1H), 7.61-7.57 (m, 1H), 7.52-7.49 (m, 1H), 5.11-5.04 (m, 1H), 1.18 (d, *J* = 6.28 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 170.2, 163.5, 149.8, 148.1, 137.6, 133.1, 131.7, 130.9, 130.6, 130.1, 128.8, 127.2, 127.0, 126.7, 126.1, 122.9, 121.6, 69.8, 21.5; HRMS (ESI⁺): calcd for C₂₀H₁₈BrN₂O₃ [M+H]⁺: 413.0495, found: 413.0496.



Isopropyl 4-bromo-8-(picolinamido)-1-naphthoate, **30a**: yellow solid (28.4 mg, 69%); mp 114-116 °C; ¹H NMR (400 MHz, CDCl₃) δ 10.27 (s, 1H), 8.71-8.69 (m, 1H), 8.34-8.28 (m, 2H), 7.93-7.88 (m, 2H), 7.80 (d, *J* = 7.68 Hz, 1H), 7.75-7.71 (m, 1H), 7.52-7.48 (m, 1H), 7.45 (d, *J* = 7.68 Hz, 1H), 5.07-5.01 (m, 1H), 1.17 (d, *J* = 6.28 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 170.0, 163.6, 149.8, 148.1, 137.6, 133.4, 132.2, 129.6, 129.1, 127.9, 127.8, 127.7, 127.2, 126.8, 126.7, 126.6,



Isopropyl 5-bromo-8-(quinoline-2-carboxamido)-1-naphthoate, **3pa**: yellow solid (28.6 mg, 62%); mp 128-130 °C; ¹H NMR (400 MHz, CDCl₃) δ 10.54 (s, 1H), 8.48 (dd, $J_I = 8.52$ Hz, $J_2 = 1.24$ Hz, 1H), 8.38 (s, 2H), 8.33 (d, J = 8.44 Hz, 1H), 7.96-7.93 (m, 2H), 7.86-7.80 (m, 2H), 7.71-7.67 (m, 2H), 7.63-7.59 (m, 1H), 5.03-4.97 (m, 1H), 1.00 (d, J = 6.28 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 170.4, 163.7, 149.5, 146.4, 137.8, 133.2, 131.9, 130.9, 130.6, 130.4, 130.2, 129.9, 129.5, 128.8, 128.3, 127.8, 127.3, 126.8, 126.1, 121.6, 119.0, 69.5, 21.0; HRMS (ESI⁺): calcd for C₂₄H₂₀N₂O₃ [M+H]⁺: 463.0652, found: 463.0653.



Isopropyl 4-bromo-8-(quinoline-2-carboxamido)-1-naphthoate, **3qa**: yellow solid (29.1 mg, 63%); mp 137-139 °C; ¹H NMR (400 MHz, CDCl₃) δ 10.54 (s, 1H), 8.37-8.31 (m, 4H), 7.99 (d, *J* = 7.44 Hz, 1H), 7.93-7.91 (m, 1H), 7.85-7.80 (m, 2H), 7.75-7.71 (m, 1H), 7.69-7.65 (m, 1H), 7.46 (d, *J* = 7.68 Hz, 1H), 5.00-4.94 (m, 1H), 0.99 (d, *J* = 6.28 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 170.1, 163.8, 149.6, 146.4, 137.7, 133.4, 132.3, 130.4, 129.9, 129.7, 129.5, 129.1, 128.3, 127.9, 127.8, 127.7, 127.6, 127.3, 126.8, 126.6, 119.1, 69.6, 21.4; HRMS (ESI⁺): calcd for C₂₄H₂₀N₂O₃ [M+H]⁺: 463.0652, found: 463.0653.



Propyl 8-(picolinamido)-1-naphthoate, **3ab**: yellow solid (30.1 mg, 90%); mp 108-110 °C; ¹H NMR (400 MHz, CDCl₃) δ 10.31 (s, 1H), 8.72-8.70 (m, 1H), 8.31-8.28 (m, 1H), 7.99 (dd, $J_I = 8.28$ Hz, $J_2 = 1.16$ Hz, 1H), 7.93-7.89 (m, 2H), 7.86-7.84 (m, 1H), 7.69 (dd, $J_I = 7.08$ Hz, $J_2 = 1.28$ Hz, 1H), 7.62 (t, J = 7.82 Hz, 1H), 7.53-7.46 (m, 2H), 4.11 (t, J = 6.82 Hz, 2H), 1.66-1.57 (m, 2H), 0.83 (t, J = 7.44 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 171.3, 163.5, 150.0, 149.1, 137.5, 135.1, 131.9, 131.6, 129.1, 128.3, 127.6, 126.8, 126.6, 126.4, 125.9, 124.6, 122.8, 67.6, 21.7, 10.3; HRMS (ESI⁺): calcd for C₂₀H₁₉N₂O₃ [M+H]⁺: 335.1390, found: 335.1393.



Hexadecyl 8-(picolinamido)-1-naphthoate, **3ac**: yellow solid (17.5 mg, 34%); mp 66-68 °C; ¹H NMR (400 MHz, CDCl₃) δ 10.32 (s, 1H), 8.71-8.70 (m, 1H), 8.30-8.28 (m, 1H), 7.99 (dd, $J_I = 8.28$ Hz, $J_2 = 1.08$ Hz, 1H), 7.93-7.88 (m, 2H), 7.85-7.83 (m, 1H), 7.68 (dd, $J_I = 7.08$ Hz, $J_2 = 1.24$ Hz, 1H), 7.62 (t, J = 7.84 Hz, 1H), 7.52-7.46 (m, 2H), 4.14 (t, J = 6.88 Hz, 2H), 1.60-1.55 (m, 2H), 1.25-1.20 (m, 26H), 0.87 (t, J = 6.68 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 171.3, 163.5, 150.1, 148.1, 137.5, 135.1, 131.9, 131.7, 129.1, 128.3, 127.5, 126.7, 126.5, 126.4, 125.9, 124.6, 122.9, 66.3, 31.9, 29.7, 29.7, 29.7, 29.6, 29.6, 29.5, 29.4, 29.2, 28.4, 25.9, 22.7, 14.1; HRMS (ESI⁺): calcd for C₃₃H₄₅N₂O₃ [M+H]⁺: 517.3425, found: 517.3427.



Cyclopentyl 8-(picolinamido)-1-naphthoate, **3ad**: yellow solid (18.7 mg, 52%); mp 95-97 °C; ¹H NMR (400 MHz, CDCl₃) δ 10.36 (s, 1H), 8.72 (d, J = 4.28 Hz, 1H), 8.29 (d, J = 7.80 Hz, 1H), 7.97 (dd, $J_1 = 8.22$ Hz, $J_2 = 1.04$ Hz, 1H), 7.92-7.88 (m, 2H), 7.83 (d, J = 8.08 Hz, 1H), 7.64-7.59 (m, 2H), 7.51-7.45 (m, 2H), 5.25-5.22 (m, 1H), 1.69-1.65 (m, 6H), 1.54-1.50 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 171.0, 163.5, 150.1, 148.1, 137.5, 135.1, 131.9, 131.7, 129.4, 128.3, 127.5, 126.7, 126.5, 126.4, 125.8, 124.6, 122.8, 78.8, 32.6, 20.8; HRMS (ESI⁺): calcd for C₂₂H₂₁N₂O₃ [M+H]⁺: 361.1547, found: 361.1548.



Hexadecyl 8-(5-bromopicolinamido)-1-naphthoate, **3ec**: yellow solid (25.5 mg, 43%); mp 65-68 °C; ¹H NMR (400 MHz, CDCl₃) δ 10.23 (s, 1H), 8.76 (d, J = 1.76 Hz, 1H), 8.20-8.17 (m, 1H), 8.04 (dd, $J_I = 8.32$ Hz, $J_2 = 2.24$ Hz, 1H), 8.00 (dd, $J_I = 8.24$ Hz, $J_2 = 1.00$ Hz, 1H), 7.90-7.84 (m, 2H), 7.71 (dd, $J_I = 7.08$ Hz, $J_2 = 1.20$ Hz, 1H), 7.62 (t, J = 7.84 Hz, 1H), 7.50-7.47 (m, 1H), 4.17 (t, J = 6.26 Hz, 2H), 1.64-1.55 (m, 2H), 1.25-1.22 (m, 26H), 0.88 (t, J = 6.80 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 171.3, 162.7, 149.3, 148.6, 140.2, 135.1, 132.1, 131.4, 128.9, 128.6, 127.7, 126.8, 126.4, 125.7, 124.6, 124.4, 124.3, 66.3, 31.9, 29.7, 29.7, 29.7, 29.6, 29.5, 29.4, 29.3, 28.5, 25.9, 22.7, 14.2; HRMS (ESI⁺): calcd for C₃₃H₄₄BrN₂O₃ [M+H]⁺: 595.2530, found: 595.2531.



3-Chloropropyl 8-(5-methoxypicolinamido)-1-naphthoate, **3de**: brown solid (20.7 mg, 52%); mp 93-95 °C; ¹H NMR (400 MHz, CDCl₃) δ 10.07 (s, 1H), 8.37 (d, J = 2.68 Hz, 1H), 8.24 (d, J = 8.64 Hz, 1H), 7.99 (dd, J_1 = 8.24 Hz, J_2 = 1.00 Hz, 1H), 7.88-7.82 (m, 2H), 7.67-7.59 (m, 2H), 7.49-7.46 (m, 1H), 7.33 (dd, J_1 = 8.68 Hz, J_2 = 2.84 Hz, 1H), 4.30 (t, J = 6.24 Hz, 2H), 3.93 (s, 3H), 3.51 (t, J = 6.34 Hz, 2H), 2.08-2.02 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 171.1, 163.4, 158.3, 142.5, 136.5, 135.0, 132.0, 131.8, 128.7, 128.2, 127.5, 126.9, 126.5, 126.0, 124.6, 124.1, 120.5, 62.8, 55.9, 41.2, 31.3; HRMS (ESI⁺): calcd for C₂₁H₂₀ClN₂O₄ [M+H]⁺: 399.1106, found: 399.1107.



3-Chloropropyl 8-(quinoline-2-carboxamido)-1-naphthoate, **3he**: yellow solid (31.4 mg, 75%); mp 104-106 °C; ¹H NMR (400 MHz, CDCl₃) δ 10.54 (s, 1H), 8.41-8.36 (m, 2H), 8.32 (d, *J* = 8.44 Hz, 1H), 8.02 (dd, *J*₁ = 8.24 Hz, *J*₂ = 1.04 Hz, 1H), 7.97-7.92 (m, 2H), 7.87-7.82 (m, 2H), 7.70-7.62 (m, 3H), 7.52-7.48 (m, 1H), 4.19 (t, *J* = 6.22 Hz, 2H), 3.32 (t, *J* = 6.38 Hz, 2H), 1.90-1.83 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 171.1, 163.6, 149.6, 146.4, 137.8, 135.1, 132.1, 131.8, 130.5, 129.8, 129.5, 128.7, 128.3, 128.3, 127.9, 127.6, 126.7, 126.6, 125.9, 124.6, 119.1, 62.6, 40.9, 31.2; HRMS (ESI⁺): calcd for C₂₄H₂₀ClN₂O₃ [M+H]⁺: 419.1157, found: 419.1159.



Benzyl 8-(5-methoxypicolinamido)-1-naphthoate, **3df**: brown oil (8.7 mg, 21%); ¹H NMR (400 MHz, CDCl₃) δ 10.17 (s, 1H), 8.31 (d, *J* = 2.76 Hz, 1H), 8.23 (d, *J* = 8.64 Hz, 1H), 7.98 (dd, *J*_{*I*} = 8.26 Hz, *J*₂ = 1.10 Hz, 1H), 7.89 (d, *J* = 7.44 Hz, 1H), 7.83 (d, *J* = 8.16 Hz, 1H), 7.67-7.59 (m, 2H), 7.47-7.43 (m, 1H), 7.32-7.28 (m, 6H), 5.22 (s, 2H), 3.91 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 171.0, 163.4, 158.2, 142.6, 136.4, 135.5, 135.0, 132.0, 131.8, 128.7, 128.5, 128.3, 128.3, 128.0, 127.4, 126.8, 126.5, 126.0, 124.6, 124.2, 120.4, 67.6, 55.8; HRMS (ESI⁺): calcd for C₂₅H₂₁N₂O₄ [M+H]⁺: 413.1496, found: 413.1499.



Allyl 8-(3-methylpicolinamido)-1-naphthoate, **3bg**: brown solid (8.0 mg, 23%); mp 119-121 °C; ¹H NMR (400 MHz, CDCl₃) δ 10.35 (s, 1H), 8.55-8.53 (m, 1H), 7.99 (dd, J_1 = 8.24 Hz, J_2 = 1.12 Hz, 1H), 7.87-7.83 (m, 2H), 7.68-7.60 (m, 3H), 7.50-7.46 (m, 1H), 7.42-7.38 (m, 1H), 5.89-5.79 (m, 1H), 5.23-5.12 (m, 2H), 4.57 (dt, J_1 = 5.77 Hz, J_2 = 1.26 Hz, 2H), 2.77 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 170.8, 165.0, 147.0, 145.4, 141.1, 136.4, 135.1, 131.9, 131.8, 131.6, 128.9, 128.2, 127.4, 126.9, 126.4, 126.2, 126.1, 124.6, 118.6, 66.4, 20.8; HRMS (ESI⁺): calcd for C₂₁H₁₉N₂O₃ [M+H]⁺: 347.1390, found: 347.1392.



Allyl 8-(quinoline-2-carboxamido)-1-naphthoate, **3hg**: brown solid (12.2 mg, 32%); mp 109-111 °C; ¹H NMR (400 MHz, CDCl₃) δ 10.54 (s, 1H), 8.41-8.35 (m, 2H), 8.31 (d, J = 8.48 Hz, 1H), 8.02-7.92 (m, 3H), 7.87-7.81 (m, 2H), 7.73-7.62 (m, 3H), 7.52-7.48 (m, 1H), 5.78-5.67 (m, 1H), 5.05-4.95 (m, 2H), 4.55 (dt, J_I = 5.76 Hz, J_2 = 1.36 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 170.8, 163.6, 149.7, 146.4, 137.7, 135.1, 132.0, 131.8, 131.5, 130.4, 129.9, 129.5, 128.8, 128.4, 128.2, 127.8, 127.5, 126.6, 126.5, 125.9, 124.7, 119.2, 118.4, 66.4; HRMS (ESI⁺): calcd for C₂₄H₁₉N₂O₃ [M+H]⁺: 383.1390, found: 383.1392.



N-(8-benzoylnaphthalen-1-yl)picolinamide, **3ah:** White solid (12.7 mg, 36%); mp 144-146 °C; ¹H NMR (400 MHz, CDCl₃) δ 9.72 (s, 1H), 8.54-8.52 (m, 1H), 8.04-8.02 (m, 1H), 7.92 (d, *J* = 7.92 Hz, 1H), 7.80-7.78 (m, 1H), 7.74-7.68 (m, 2H), 7.64-7.60 (m, 1H), 7.56-7.52 (m, 1H), 7.50-7.48 (m, 2H), 7.42-7.32 (m, 3H), 7.14-7.10 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 199.4, 163.1, 149.2, 147.9, 137.0, 136.9, 136.0, 135.1, 133.2, 131.7, 130.5, 130.0, 128.0, 127.9, 127.8, 126.9, 126.6, 126.5, 126.2, 124.9, 122.1; HRMS (ESI⁺): calcd for C₂₃H₁₆N₂O₂ [M+H]⁺: 353.1285, Found: 353.1287.



N-(8-(4-methylbenzoyl)naphthalen-1-yl)picolinamide, 3ai: White solid (13.9 mg, 38%); mp 166-

168 °C; ¹H NMR (400 MHz, CDCl₃) δ 9.72 (s, 1H), 8.55-8.53 (m, 1H), 8.03-8.00 (m, 1H), 7.91 (d, J = 8.20 Hz, 1H), 7.81-7.79 (m, 1H), 7.75-7.68 (m, 2H), 7.63-7.59 (m, 1H), 7.55-7.52 (m, 1H), 7.42-7.38 (m, 4H), 6.91 (d, J = 7.96 Hz, 2H), 2.27 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 199.2, 163.2, 149.3, 147.9, 144.1, 136.8, 136.2, 135.1, 134.6, 131.8, 130.4, 130.2, 128.6, 127.9, 127.7, 126.8, 126.5, 126.4, 126.2, 124.9, 122.1, 21.6; HRMS (ESI⁺): calcd for C₂₄H₁₈N₂O₂ [M+H]⁺: 367.1441, Found: 367.1442.



N-(8-(4-chlorobenzoyl)naphthalen-1-yl)picolinamide, **3aj:** White solid (11.8 mg, 36%); mp 174-177 °C; ¹H NMR (400 MHz, CDCl₃) δ 9.66 (s, 1H), 8.54 (d, J = 4.72 Hz, 1H), 8.03 (d, J = 8.12 Hz, 1H), 7.92 (d, J = 8.04 Hz, 1H), 7.82-7. 81 (m, 1H), 7.77-7.73 (m, 1H), 7.71-7.69 (m, 1H), 7.64-7.61 (m, 1H), 7.56-7.53 (m, 1H), 7.44-7.37 (m, 4H), 7.07 (d, J = 8.56 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 198.2, 163.2, 149.1, 147.9, 139.7, 137.1, 135.4, 135.3, 135.1, 131.6, 131.3, 130.7, 128.2, 128.2, 128.0, 127.2, 126.7, 126.4, 126.4, 124.9, 122.2; HRMS (ESI⁺): calcd for C₂₃H₁₅ClN₂O₂ [M+H]⁺: 387.0895, Found: 387.0894.



Benzo[cd]indol-2(1H)-one, **4a**: yellow solid (18.6 mg, 55%); mp 173-176 °C; ¹H NMR (400 MHz, CDCl₃) δ 9.10 (s, 1H), 8.11 (d, J = 7.00 Hz, 1H), 8.05 (d, J = 8.08 Hz, 1H), 7.76-7.72 (m, 1H), 7.56 (d, J = 8.44 Hz, 1H), 7.48-7.44 (m, 1H), 7.03 (d, J = 7.00 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 170.4, 137.2, 131.2, 129.4, 128.7, 126.8, 126.3, 124.5, 120.4, 106.7; HRMS (ESI⁺): calcd for C₁₁H₈NO [M+H]⁺: 170.0600, found: 170.0599.



1-Ethylbenzo[cd]indol-2(1H)-one, **5a**: yellow solid (189 mg, 96%); mp 65-68 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.00 (d, J = 6.96 Hz, 1H), 7.91 (d, J = 8.12 Hz, 1H), 7.64-7.60 (m, 1H), 7.45-7.37 (m, 2H), 6.83 (d, J = 6.88 Hz, 1H), 3.92 (q, J = 7.24 Hz, 2H), 1.34 (t, J = 7.24 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 167.7, 139.0, 130.6, 129.0, 128.5, 128.4, 126.7, 125.1, 124.0, 120.1, 104.8, 34.9, 14.1; HRMS (ESI⁺): calcd for C₁₃H₁₂NO [M+H]⁺: 198.0913, found: 198.0915.



1-Ethyl-6-nitrobenzo[cd]indol-2(1H)-one, 6a: yellow solid (155 mg, 67%); mp 158-161 °C; ¹H

NMR (400 MHz, CDCl₃) δ 8.89 (d, J = 8.52 Hz, 1H), 8.56 (d, J = 8.00 Hz, 1H), 8.06 (d, J = 6.96 Hz, 1H), 7.86 (t, J = 7.76 Hz, 1H), 6.92 (d, J = 8.00 Hz, 1H), 3.99 (q, J = 7.20 Hz, 2H), 1.40 (t, J = 7.20 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 167.6, 145.6, 138.9, 131.9, 129.9,129.9, 126.0, 125.6, 125.3, 122.5, 102.9, 35.2, 13.9; HRMS (ESI⁺): calcd for C₁₃H₁₁N₂O₃ [M+H]⁺: 243.0764, found: 243.0762.



1-Ethyl-6-nitrobenzo[cd]indol-2(1H)-one, **7a**: red solid (105 mg, 77%); mp 181-183 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.07 (d, J = 7.00 Hz, 1H), 8.00 (d, J = 8.16 Hz, 1H), 7.69-7.65 (m, 1H), 6.73 (d, J = 7.44 Hz, 1H), 6.64 (d, J = 7.44 Hz, 1H), 3.94 (q, J = 7.24 Hz, 2H), 3.41 (s, 2H), 1.35 (t, J = 7.24 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 167.3, 138.4, 131.1, 127.6, 127.4, 125.6, 125.3, 124.3, 121.5, 109.7, 106.5, 34.9, 14.1; HRMS (ESI⁺): calcd for C₁₃H₁₃N₂O [M+H]⁺: 213.1022, found: 213.1023.



5-bromo-N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-2-methoxybenzenesulfonamide, **8a**: yellow solid (202 mg, 88%); mp 209-211 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.21 (d, J = 8.28 Hz, 1H), 8.00 (d, J = 6.96 Hz, 1H), 7.80-7.79 (m, 2H), 7.69-7.65 (m, 1H), 7.53 (dd, J_I = 8.80 Hz, J_2 = 2.48 Hz, 1H), 7.17 (d, J = 7.56 Hz, 1H), 6.90 (d, J = 8.88 Hz, 1H), 6.71 (d, J = 7.60 Hz, 1H), 4.06 (s, 3H), 3.88 (q, J = 7.20 Hz, 2H), 1.30 (t, J = 7.20 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 167.6, 155.4, 138.1, 137.6, 133.2, 129.0, 128.2, 127.0, 126.8, 126.4, 126.1, 125.5, 124.8, 124.4, 113.9, 112.8, 104.8, 56.7, 35.0, 14.0; HRMS (ESI⁺): calcd for C₂₀H₁₈BrN₂O₄S [M+H]⁺: 461.0165 , found: 461.0167.

5. References

[1]. R. Shang, L. Ilies, E. Nakamura, J. Am. Chem. Soc. 2015, 137, 7660.

[2]. (a) X. Xue, Y. Zhang, Z. Liu, M. Song, Y. Xing, Q. Xiang, Z. Wang, Z. Tu, Y. Zhou, K. Deng, Y. Xu, J. Med. Chem. 2016, 59, 1565; (b) Y. Feng, S. Xiao, Y. Chen, H. Jiang, N. Liu, C. Luo, S. Chen, H. Chen, Eur. J. Med. Chem. 2018, 152, 264.

6. The Single Crystal X-ray Diffraction Study

The Single Crystal X-ray Diffraction Study of **3na**



CCDC 1956109 (**3na**) contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre *via* www. ccdc.cam.ac.uk/data_request/cif.

Table S3 Crystal data and structure refinement for CCDC 1956109.

Empirical formula	$C_{20}H_{17}BrN_2O_3$
Formula weight	413.26
Temperature/K	293(2)
Crystal system	monoclinic
Space group	$P2_1/c$
a/Å	16.6385(13)
b/Å	14.3268(8)
c/Å	7.7041(5)
α/°	90
β/°	100.731(7)
γ/°	90
Volume/Å ³	1804.3(2)
Ζ	4
$\rho_{calc}g/cm^3$	1.521
µ/mm ⁻¹	3.296
F(000)	840.0

Crystal size/mm ³	$0.19 \times 0.14 \times 0.11$
Radiation	$CuK\alpha$ ($\lambda = 1.54184$)
2Θ range for data collection/°	8.206 to 134.16
Index ranges	$-19 \le h \le 13, -17 \le k \le 16, -8 \le l \le 9$
Reflections collected	6920
Independent reflections	3221 [$R_{int} = 0.0468, R_{sigma} = 0.0652$]
Data/restraints/parameters	3221/0/242
Goodness-of-fit on F ²	1.053
Final R indexes [I>= 2σ (I)]	$R_1 = 0.0486, wR_2 = 0.1062$
Final R indexes [all data]	$R_1 = 0.0755, wR_2 = 0.1265$
Largest diff. peak/hole / e Å ⁻³	0.35/-0.43

7. Copies of ¹H, ¹³C NMR Spectra for the Products





































































